SUMMARY Radiotracer kinetics were used to evaluate the activity of the sympathetic nervous system in 10 patients who had had unstable ischaemic symptoms within the previous 12 weeks and 10 
The sympathetic nervous system has a profound effect on the susceptibility of the ischaemic myocardium to serious ventricular arrhythmias,'2 and the cardiac autonomic nervous system has been implicated in sudden cardiac death.3 Experimental coronary occlusion, however, does not increase coronary venous overflow of noradrenaline45 but sympathetic responsiveness was temporarily related to vulnerability to arrhythmia in open chest anaesthetised dogs. 6 Coronary occlusion increases local concentrations of cyclic adenosine monophosphate, possibly because of an increase in sympathetic activity.7 In addition to local exocytotic catecholamine release via reflex mechanisms or local nerve terminal depolarisation, ischaemia itself may result in the direct release of noradrenaline via outward transport from the nerve terminal mediated by a carrier.8 Little is known about the response of the sympathetic nervous system to myocardial ischaemia in human beings.
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Accepted for publication 18 August 1988 Assessment of sympathetic tone in clinical research has often been based on the measurement of concentrations ofnoradrenaline in the venous plasma for overall sympathetic tone and of the venoarterial difference in noradrenaline concentration for sympathetic tone to individual organs. These better assessment of cardiac sympathetic activity than was possible before. 238 Noradrenaline kinetics in ischaemic heart disease The aim of this study was to evaluate the effects on cardiac and overall sympathetic activity in patients with coronary artery disease of recent unstable ischaemic symptoms and of a short period of myocardial ischaemia induced by atrial pacing.
Patients and methods

PATIENTS
We studied 20 patients (table 1) arterial blood and blood from the coronary sinus were taken 30 minutes after the start of the infusion. In 10 subjects with stable angina and five subjects with unstable symptoms atrial pacing via the Baim catheter was then started and the rate was increased to the maximum sustainable rate (the fastest rate not causing severe angina or Wenckebach atrioventricular block). Pacing increased the heart rate from 62 beats/minute at rest (range 48-70) to 110 (94-123) beats/minute. In 13 patients angina developed during pacing. In nine of these ST segment depression on the standard 12 lead surface electrocardiogram was > 1 mm. Arterial and coronary sinus blood samples (10 ml each) were taken after 10 and 20 minutes pacing and again 10 minutes after the end of pacing. Coronary sinus blood flow was measured immediately before each sampling time. minutes. Blood samples were collected into chilled lithium heparin tubes, centrifuged at 4°C, and the plasma was frozen on dry ice and stored at -20°C for up to three months. Sodium metabisulphite at a final concentration of 1 mmol/l was used as an antioxidant. Plasma noradrenaline was measured by high performance liquid chromatography. 6 The normal range in our laboratory is 120-300 pg/ml and the within day coefficient of variation is 4%. Plasma [ 
STATISTICAL ANALYSIS
Analysis ofvariance was used to assess the differences between the data at the four time points of the pacing protocol. The data on noradrenaline kinetics were log transformed because their distribution was skewed. Differences between patients with stable and unstable symptoms were analysed by a two tailed MannWhitney U test. Results were deemed to be significant at the 500 level. Results are expressed as the mean (1 SEM).
Results
BASAL NORADRENALINE KINETICS IN PATIENTS WITH STABLE AND RECENT UNSTABLE SYMPTOMS (table 2, figs 1 and 2)
The ranges of basal concentrations of noradrenaline in the coronary sinus (62-1438 pg/ml) and of basal cardiac noradrenaline spillover (2-76 ng/min) were large. Patients with chronic stable angina had much lower concentrations of noradrenaline in the coronary sinus and much lower cardiac noradrenaline spillover than did patients with recent unstable ischaemic symptoms. Values were highest in a man The ratio of cardiac noradrenaline spillover in the group with recent unstable angina compared with that in the patients with stable angina was 4-0: 1. For whole body spillover the ratio between the same two groups was only 1-5: 1. Similarly the ratio of cardiac to whole body noradrenaline spillover was greater in the group with recent unstable angina (0-065 (0-013)) than in the group with stable angina (0-021 (0-005)) (p < 0-01, fig 2) , so there was evidence of a selective increase in cardiac sympathetic activity in patients with recent unstable angina.
There was no significant correlation between left ventricular ejection fraction and cardiac noradrenaline spillover (r = -030, p = NS). Similarly there was no significant correlation between left ventricular end diastolic pressure and cardiac noradrenaline spillover (r = 0-36, p = NS).
NORADRENALINE KINETICS DURING ATRIAL PACING (figs 3, 4, 5, and 6) Atrial pacing increased coronary sinus plasma flow from 55 (5) ml/min to 78 (7) ml/min but, as a result of a decline in the fractional extraction ofnoradrenaline by the coronary circulation from 71 (3)% to 59 (4)%, cardiac noradrenaline clearance was not significantly altered by pacing (fig 3) . Despite the development of myocardial ischaemia in most of the subjects there was a trend towards a decline in coronary sinus noradrenaline concentration during atrial pacing and spillover was seen in response to atrial pacing in either groups (stable n = 10, unstable n = 5) ( fig 5) . Atrial pacing resulted in a modest rise in whole body noradrenaline clearance, from 1311 (138) ml/ min to 1508 (213) ml/min. This was associated with a small rise in noradrenaline spillover to plasma and no change in arterial noradrenaline concentration (fig 6) . There was no difference in the cardiac or whole body noradrenaline kinetics between 10 and 20 minutes pacing, confirming that a new steady state had been reached. 1-0 and at rest the heart, with its rich sympathetic innervation, extracts about 70% ofthe noradrenaline entering the coronary circulation. Because, as this study shows, cardiac noradrenaline uptake may be profoundly altered by manoeuvres that alter blood flow, it is not possible to come to meaningful conclusions about the sympathetic tone to a given organ simply by measuring venoarterial differences in noradrenaline concentration and organ blood flow. The use of steady state radiotracer methods overcomes this difficulty and allows sympathetic tone to be more reliably estimated. Two previous studies have evaluated concentrations of catecholamine in the coronary sinus during atrial pacing to ischaemia in man. One found that "myocardial noradrenaline release" increased in response to atrial pacing but to a greater extent in normal controls than in patients with ischaemic heart disease.'8 A modest increase in concentration of noradrenaline in the coronary sinus was shown during atrial pacing to angina but there was no significant increase in arterial noradrenaline concentration. The second, conversely, reported a decrease in "myocardial noradrenaline overflow" during atrial pacing to angina, and showed a modest increase in arterial noradrenaline concentration but no significant change in coronary sinus noradrenaline. '9 In anaesthetised dogs epicardial pacing did not increase cardiac noradrenaline spillover.'2 Robertson et al measured coronary sinus and arterial noradrenaline concentrations during the course of spontaneous coronary artery spasm.20 No changes were seen early during ischaemia. Towards the end ofischaemia both arterial and coronary sinus concentrations of noradrenaline were increased, although venoarterial difference in concentration was little changed and coronary sinus blood flow was not measured.
Hasking et al measured resting cardiac noradrenaline spillover using radiotracer techniques in 15 subjects with normal left ventricular function, of whom five had ischaemic heart disease, and found mean cardiac noradrenaline spillover to be 5 ng/ min"; this accorded with the findings in the present study, but no previous study has used radiotracers to assess the response of the sympathetic nervous system to myocardial ischaemia in man.
BASAL NORADRENALINE KINETICS IN ISCHAEMIC HEART DISEASE
In subjects with stable angina cardiac and whole body noradrenaline spillover were similar to those previously reported for normal subjects2' and to our patients with normal coronary arteries undergoing coronary arteriography (unpublished data). There is, therefore, no evidence ofeither generalised or cardiac sympathetic overactivity in stable angina, even when McCance, Forfar the angina is severe and the underlying coronary disease extensive. Those with similar severity of underlying disease but with unstable ischaemic symptoms within the previous 12 weeks had much higher basal cardiac noradrenaline spillover than patients with stable angina, although whole body noradrenaline spillover was not significantly different. This represents a selective and sustained increase in cardiac efferent sympathetic tone in these high risk patients.
Although systemic hypertension was diagnosed in similar numbers of patients in each group, blood pressure was significantly higher in the group with recent unstable angina. Transient Noradrenaline kinetics in ischaemic heart disease despite the development of angina in most patients. There is thus no evidence that myocardial ischaemia per se, at least of the degree induced in this study, causes cardiac or generalised sympathetic activation.
LIMITATIONS OF THE STUDY
Regional heterogeneity within the heart Sampling from the coronary sinus does have certain theoretical disadvantages. Samples taken from this site during angina will inevitably contain venous effluent from both ischaemic and non-ischaemic areas and the relative contribution of each is not assessable. In the dog model it is possible to cannulate local veins from ischaemic and non-ischaemic territories6 but this cannot be done in man. However, the severity and distribution of the coronary disease in our subjects make it highly likely that, when they developed myocardial ischaemia, the coronary sinus samples contained a substantial proportion of venous effluent from ischaemic myocardium (14 of the 15 paced patients had significant disease of the left anterior descending artery and 12 had significant disease of the circumflex artery). Thus any important increase in cardiac sympathetic activity, whether or not it was localised to the ischaemic area, should have been detectable. Medications All the patients in the study were on antianginal medication, which we and our ethics committee felt should not be withdrawn. The possibility that this may have modified the sympathetic response to myocardial ischaemia cannot be excluded. Although ,B adrenoreceptor antagonists (the most likely drugs to alter sympathetic activity) decrease noradrenaline clearance, at least in the short term, they do not change total noradrenaline spillover." It therefore seems unlikely that the patients' drug treatment was responsible for the observed lack of increase in cardiac noradrenaline spillover when myocardial ischaemia was induced by atrial pacing. Many experimental studies have shown that the combination of myocardial ischaemia and sympathetic stimulation is a powerful cause of ventricular arrhythmias, which are responsible for sudden cardiac death in most cases.37 It is likely that the arrhythmogenic action of sympathetic stimulation operates at several levels and sensitises the myocardium to the arrhythmogenic effects of myocardial ischaemia through various mechanisms, including coronary blood flow regulation, myocardial oxygen demand, and promotion of automatic and re-entrant pathways and triggered activity. 28 The demonstration in this study of increased cardiac sympathetic tone in unstable ischaemic syndromes is therefore of considerable importance in view of the increased risk of sudden death in such patients. The benefit in terms of mortality that is associated with the use of P blockers after myocardial infarction is due to a reduction in sudden death,'9 and a reduction in the response of the target organ to sympathetic stimulation may be the mechanism for this protective effect. 
